25,365 Shares in Phreesia, Inc. $PHR Bought by Petrus Trust Company LTA

Key Points

• Petrus Trust Company LTA acquired 25,365 shares in Phreesia, Inc. (NYSE:PHR) during the 1st quarter, valued at approximately $648,000.
• Phreesia's shares have experienced a 10% decline, with the stock currently priced at $28.09, reflecting a market capitalization of $1.67 billion.
• Thirteen analysts have rated Phreesia with a "Buy" rating and set a consensus target price of $33.31 for the stock.

Petrus Trust Company LTA acquired a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,365 shares of the company's stock, valued at approximately $648,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. KBC Group NV purchased a new position in Phreesia during the first quarter worth $74,000. CWM LLC boosted its stake in Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares during the period. Smartleaf Asset Management LLC boosted its stake in Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after buying an additional 1,825 shares during the period. GAMMA Investing LLC boosted its stake in Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after buying an additional 5,621 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in Phreesia during the fourth quarter worth $163,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Stock Down 10.0%

Shares of PHR opened at $28.09 on Friday. The firm has a market capitalization of $1.67 billion, a P/E ratio of -66.88 and a beta of 0.72. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $32.76. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average price of $28.34 and a 200-day moving average price of $26.53.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. The firm had revenue of $117.26 million during the quarter, compared to analyst estimates of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 9.00%. The business's revenue was up 14.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. Equities research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on PHR shares. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. DA Davidson started coverage on shares of Phreesia in a research note on Friday. They set a "buy" rating and a $33.00 price objective for the company. Mizuho started coverage on shares of Phreesia in a research note on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price objective for the company. Needham & Company LLC boosted their target price on shares of Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Friday. Finally, Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. Thirteen analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $33.31.

Insider Transactions at Phreesia

In related news, insider David Linetsky sold 17,445 shares of Phreesia stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $29.73, for a total value of $518,639.85. Following the completion of the sale, the insider directly owned 174,002 shares in the company, valued at $5,173,079.46. The trade was a 9.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of Phreesia stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the sale, the director owned 22,037 shares of the company's stock, valued at $609,763.79. The trade was a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 119,874 shares of company stock valued at $3,587,618 over the last three months. 5.50% of the stock is currently owned by corporate insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.